Constitutive activation of B-Raf in the mouse germ line provides a model for human cardio-facio-cutaneous syndrome

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 12, 2011, Pages 5015-5020

  Urosevic, Jelena ^a,f   Sauzeau, Vincent ^b,g   Soto Montenegro, María L ^c   Reig, Santiago ^c   Desco, Manuel ^c,d   Burkitt Wright, Emma M ^e   Cañamero, Marta ^a   Mulero, Francisca ^a   Ortega, Sagrario ^a   Bustelo, Xosé R ^b   Barbacid, Mariano ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b Salamanca Spain   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d UNIVERSIDAD CARLOS III DE MADRID   (Spain)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^g L INSTITUT DU THORAX   (France)

Author keywords

B Raf signaling; Chromaffin derived tumor; Developmental defects

Indexed keywords

B RAF KINASE; CATECHOLAMINE;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOMEGALY; CATARACT; CONTROLLED STUDY; EPILEPSY; FACE DYSMORPHIA; FEMALE; FERTILITY; GENE EXPRESSION; HISTOPATHOLOGY; KIDNEY DISEASE; LEOPARD SYNDROME; LIFESPAN; MALE; MOUSE; NEUROENDOCRINE TUMOR; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; UPREGULATION;

MUS;

EID: 79953186113     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1016933108     Document Type: Article

References (30)

1. Davies H, et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417:949-954. (Pubitemid 34716871)
2. Wellbrock C, Karasarides M, Marais R (2004) The RAF proteins take centre stage. Nat Rev Mol Cell Biol 5:875-885. (Pubitemid 39486539)
3. Wan PT, et al. (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855-867. (Pubitemid 38410730)
4. Niihori T, et al. (2006) Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat Genet 38:294-296.
5. Rodriguez-Viciana P, et al. (2006) Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science 311:1287-1290. (Pubitemid 43334718)
6. Schubbert S, Shannon K, Bollag G (2007) Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 7:295-308.
7. Brems H, et al. (2007) Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat Genet 39:1120-1126. (Pubitemid 47340658)
8. Tidyman WE, Rauen KA (2009) The RASopathies: Developmental syndromes of Ras/MAPK pathway dysregulation. Curr Opin Genet Dev 19:230-236.
9. Roberts A, et al. (2006) The cardiofaciocutaneous syndrome. J Med Genet 43:833-842. (Pubitemid 44787108)
10. Rodriguez-Viciana P, Rauen KA (2008) Biochemical characterization of novel germline BRAF and MEK mutations in cardio-facio-cutaneous syndrome. Methods Enzymol 438:277-289.
11. Gripp KW, et al. (2007) Further delineation of the phenotype resulting from BRAF or MEK1 germline mutations helps differentiate cardio-facio-cutaneous syndrome from Costello syndrome. Am J Med Genet A 143A:1472-1480. (Pubitemid 47051026)
12. Narumi Y, et al. (2007) Molecular and clinical characterization of cardio-facio-cutaneous (CFC) syndrome: Overlapping clinical manifestations with Costello syndrome. Am J Med Genet A 143A:799-807. (Pubitemid 46556165)
13. Heidorn SJ, et al. (2010) Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140:209-221.
14. Aoki Y, et al. (2005) Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat Genet 37:1038-1040. (Pubitemid 41486653)
15. Bollag G, et al. (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467:596-599.
16. Flaherty KT, et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819.
17. Mercer K, et al. (2005) Expression of endogenous oncogenic V600EB-raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts. Cancer Res 65:11493-11500. (Pubitemid 41821707)
18. Schuhmacher AJ, et al. (2008) A mouse model for Costello syndrome reveals an Ang II-mediated hypertensive condition. J Clin Invest 118:2169-2179. (Pubitemid 351872335)
19. Stringer JL (1996) Repeated seizures increase GFAP and vimentin in the hippocampus. Brain Res 717:147-153.
20. Pekny M, Nilsson M (2005) Astrocyte activation and reactive gliosis. Glia 50:427-434. (Pubitemid 40780846)
21. Dankort D, et al. (2007) A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev 21:379-384.
22. Dhomen N, et al. (2009) Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 15:294-303.
23. Bryant J, Farmer J, Kessler LJ, Townsend RR, Nathanson KL (2003) Pheochromocytoma: The expanding genetic differential diagnosis. J Natl Cancer Inst 95: 1196-1204. (Pubitemid 37069549)
24. Armour CM, Allanson JE (2008) Further delineation of cardio-facio- cutaneous syndrome: Clinical features of 38 individuals with proven mutations. J Med Genet 45:249-254. (Pubitemid 351518732)
25. Nyström AM, et al. (2008) Noonan and cardio-facio-cutaneous syndromes: Two clinically and genetically overlapping disorders. J Med Genet 45:500-506.
26. Chen X, et al. (2009) Endogenous expression of Hras(G12V) induces developmental defects and neoplasms with copy number imbalances of the oncogene. Proc Natl Acad Sci USA 106:7979-7984.
27. Anastasaki C, Estep AL, Marais R, Rauen KA, Patton EE (2009) Kinase-activating and kinase-impaired cardio-facio-cutaneous syndrome alleles have activity during zebrafish development and are sensitive to small molecule inhibitors. Hum Mol Genet 18:2543-2554.
28. Sauzeau V, et al. (2006) Vav3 proto-oncogene deficiency leads to sympathetic hyperactivity and cardiovascular dysfunction. Nat Med 12:841-845. (Pubitemid 44050076)
29. Sauzeau V, Jerkic M, López-Novoa JM, Bustelo XR (2007) Loss of Vav2 proto-oncogene causes tachycardia and cardiovascular disease in mice. Mol Biol Cell 18:943-952. (Pubitemid 46399499)
30. Sauzeau V, Sevilla MA, Montero MJ, Bustelo XR (2010) The Rho/Rac exchange factor Vav2 controls nitric oxide-dependent responses in mouse vascular smooth muscle cells. J Clin Invest 120:315-330.